Stevanato (STVN) Declined Due to Anticipation of Soft Quarter Ahead

Core Insights - The Alger Small Cap Focus Fund's fourth-quarter 2025 investor letter highlights a strong performance in the US equity market, with the S&P 500 rising by 2.7% due to better-than-expected corporate earnings and a supportive macroeconomic environment [1] - The letter notes a divergence in market performance, particularly regarding AI investments, which face skepticism due to various challenges [1] - The Fund's Class A shares outperformed the Russell 2000 Growth Index, with contributions from the Utilities and Financials sectors, while Consumer Discretionary and Information Technology sectors negatively impacted performance [1] Company Insights - Stevanato Group S.p.A. (NYSE:STVN) is identified as a key holding, specializing in pharmaceutical-grade glass packaging for the biopharma and healthcare industries [2][3] - The stock of Stevanato Group experienced a one-month return of -3.80% and a 52-week decline of 13.57%, closing at $19.75 per share with a market capitalization of $5.392 billion as of January 16, 2026 [2] - Concerns regarding Stevanato's performance stem from shipment timing issues, with expectations for fourth-quarter results being lower due to earlier shipments in the third quarter, alongside worries about competition from oral GLP-1 drugs affecting demand for its injectable delivery components [3]